Peptide questions · IGF-1 LR3

IGF-1 LR3 side effects: what studies and users report

Reviewed Evidence: EmergingPublished by PepVault

The side effects most commonly reported for IGF-1 LR3 are low blood sugar symptoms (shakiness, sweating, light-headedness), hunger and injection site reaction, among 5 the library lists; its evidence in people comes from small studies without a control group and from clinical use.

Its safety note opens: Low blood sugar is the published risk of the IGF-1 class, and it is the one thing to be straightforward about.

What is commonly reported with IGF-1 LR3

  • Low blood sugar symptoms (shakiness, sweating, light-headedness)
  • Hunger
  • Injection site reaction
  • Water retention
  • Joint ache

Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.

Each effect, and the other growth hormone compounds the library lists it for
EffectAlso listed for (of 13)
Low blood sugar symptoms (shakiness, sweating, light-headedness)None: listed for IGF-1 LR3 alone
HungerNone: listed for IGF-1 LR3 alone
Injection site reaction4: Sermorelin, Tesamorelin, PEG-MGF, Follistatin-344
Water retention9: Ipamorelin, CJC-1295 with DAC, CJC-1295 no DAC, Sermorelin and 5 more
Joint acheNone: listed for IGF-1 LR3 alone
A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Track IGF-1 LR3 in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Which IGF-1 LR3 side effects the growth hormone group shares

Across the 14 growth hormone compounds in the library, the effects listed most often are water retention (10 of 14), headache (5 of 14), injection site reaction (5 of 14) and fatigue (4 of 14). IGF-1 LR3 shares 2 of its 5 listed effects with at least one other growth hormone compound; low blood sugar symptoms (shakiness, sweating, light-headedness), hunger and joint ache are listed for IGF-1 LR3 alone.

What the IGF-1 LR3 safety notes say

The library’s safety note

Low blood sugar is the published risk of the IGF-1 class, and it is the one thing to be straightforward about. IGF-1 acts partly like insulin: it pushes glucose into muscle and damps the liver's glucose output. In the approved human IGF-1 drug, mecasermin (Increlex, a copy of natural IGF-1 rather than this analogue), low blood sugar was reported by 30 of 71 children in the trials, five of them severely and four with a seizure or loss of consciousness; it was most frequent in the first month and was generally avoided by eating within about 20 minutes either side of a dose. A severe low — someone confused, unrousable or fitting — is a medical emergency, not something to wait out. In pigs, the IGF-1 variants that bind the binding proteins poorly, LR3 among them, lowered glucose two to three times more potently than IGF-1 and kept it down far longer; a related variant did the same in marmosets. Beyond glucose, no toxicology or long-term study of IGF-1 LR3 in people exists; the approved IGF-1 drug's label also carries raised intracranial pressure, enlarged tonsils, allergic reactions including anaphylaxis, and post-marketing reports of malignant tumors with a monitoring instruction, and in rodents doses above the maximum tolerated dose produced skin and mammary tumors. Product identity is its own issue: a vial sold on the black market and analyzed in Cologne held His-tagged Long-R3-IGF-I, a laboratory version still carrying its purification tag, whose effects in people have never been described. For athletes: IGF-1 and its analogues are prohibited at all times under the 2026 WADA list (S2.3). Discuss with your clinician.

The library’s interaction note

No human interaction study of IGF-1 LR3 exists. The interaction that matters is pharmacological rather than metabolic: anything else that lowers blood glucose — insulin, sulfonylureas, GLP-1 drugs, hard fasted training — stacks with its insulin-like action, and the approved IGF-1 drug's patient information asks families to tell the doctor about insulin or other diabetes medicines, because their dose may need to change. Growth hormone and GH secretagogues raise your own IGF-1, so adding an IGF-1 analogue loads the same arm twice. In pigs, infused LR3 suppressed the animals' own GH, insulin, IGFBP-3 and IGF-1, which is the opposite of what a user expects from it. Discuss any prescription medications, and especially any diabetes medication, with your clinician.

These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.

Where the IGF-1 LR3 reports come from

The library rates the evidence on IGF-1 LR3 as emerging: mostly preclinical, with limited human data.

Of the library’s 7 research notes on IGF-1 LR3, 1 rest on clinical data, 3 on animal studies and 3 on community reports.

Our 4 study pages on IGF-1 LR3: 1 animal study (pigs and marmoset monkeys), 1 animal study (guinea pigs) and 2 animal studies (rats).

So the effects listed for IGF-1 LR3 come from uncontrolled studies and use in people, not from placebo-controlled trials.

Questions people ask

What are the side effects of IGF-1 LR3?

The side effects most commonly reported for IGF-1 LR3 are low blood sugar symptoms (shakiness, sweating, light-headedness), hunger and injection site reaction, among 5 the library lists; its evidence in people comes from small studies without a control group and from clinical use.

Do IGF-1 LR3’s side effects come from human studies?

The library rates the evidence on IGF-1 LR3 as emerging, and its evidence in people comes from small studies without a control group and from clinical use.

Which IGF-1 LR3 side effects are its own?

Among the growth hormone compounds, the library lists low blood sugar symptoms (shakiness, sweating, light-headedness), hunger and joint ache for IGF-1 LR3 alone.

Does IGF-1 LR3 interact with other medicines?

The library’s interaction note on IGF-1 LR3 begins: No human interaction study of IGF-1 LR3 exists.

More on IGF-1 LR3

Track it in the app

PepVault for iPhone

Track IGF-1 LR3 in PepVault

Log each dose and any side effect beside it, so you can see what changed and when.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo